News 89bio shows its NASH hand, boosting FGF21 concept Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
News NICE backs first targeted therapy for ALK+ lung cancer Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.